Table 2. Results of NGS.

Patient	Sex	Age	Tumor 1	Abundance (%)	Tumor 2	Abundance (%)
1	Female	58	CTCF gene mutation	10.3	Exon 21 L858R mutation (EGFR)	13.3
			Exon 21 L858R mutation (EGFR)	37.4	Exon 21 p.H870delinsHD mutation (EGFR)	13.3
2	Male	61	K601E mutation (BRAF)	12.4	Exon 2 G12V (KRAS)	15.8
			Exon 2 G12V (KRAS)	0.9
3	Female	67	D1345fs mutation (EP300)	12.6	Exon 21 L858R mutation (EGFR)	2.7
			G245fs mutation (TP53)	25.5	G245fs mutation (TP53)	0.3
			Exon 19 p.745_750del mutation (EGFR)	47.9	Exon 19 p.745_750del mutation (EGFR)	0.7
4	Female	62	E1649X mutation (ATRX)	3.5	L289fs mutation (BMPR1A)	9.4
			c.640-20_642delinsC mutation (HDAC2)	4.8	Exon 21 L858R mutation (EGFR)	12.4
			E307X mutation (NBN)	5.4
			Exon19 p.746_750del mutation (EGFR)	23.3

NGS, next generation sequencing.